Using an extensive series of deletion and site-speci®c mutation constructs, we have identi®ed ®ve new phosphorylation sites in c-Myc in the N-terminal transactivation domain and near the C-terminal DNA binding/heterodimerization domain. We have also found that Thr-58 phosphorylation is regulated by speci®c cellular events. When c-Myc is overexpressed in cells Thr-58 phosphorylation was greatly enhanced in the overexpressed, exogenous c-Myc as compared with the endogenous protein. In contrast, an inhibition of Thr-58 phosphorylation and an enhancement of Serine 62 phosphorylation was observed in c-Myc from immortalized cells compared with primary cells. No signi®cant changes in c-Myc phosphorylation were found when transformed and nontransformed cells were compared. Finally, mutations at these phosphorylation sites, either individually or in combination with previously described sites, did not aect the ability of c-Myc to transactivate through the CACGTG Myc/Max DNA binding sites. These results further suggest that either the molecular role for c-Myc phosphorylation does not involve modulating transcriptional activity of c-Myc or that the CACGTG site does not represent a physiological promoter element.
Introduction
Numerous studies have demonstrated a critical role for the c-myc gene in the control of cell proliferation Spencer and Groudine, 1991; Marcu et al., 1992) . Evidence has accumulated that the c-Myc proteins function as transcription factors with their dimerization partner, Max, through an E-box sequence, CACGTG or EMS (E-box myc site) (Blackwood and Eisenman, 1991; Kretzner et al., 1992) . The heterodimerization/DNA binding domain is located at the C-terminus, while the transactivation domain is located in the N-terminus (Kato et al., 1990) . These highly conserved domains have been shown to be required for cotransformation of rat embryo ®broblasts with activated Ras protein and for the anchorage-independent growth of Rat 1A cells (Sarid et al., 1987; Stone et al., 1987) .
Phosphorylation has been found to regulate the activities of many transcription factors and protooncogenes (Hunter and Karin, 1992; Meek and Street, 1992) . Several studies have investigated the role of phosphorylation in c-Myc function, and most of these focused on the casein kinase II sites in the C-terminal domain (Luscher et al., 1989) or the Thr-58/Ser-62 sites in the N-terminus transactivation domain. The functional relevance of the casein kinase II sites at Ser-347/348 near the basic region is not known. c-Myc protein mutated at these sites is unaected in its ability to co-transform Rat-1 cells with the bcr-abl oncogene (Street et al., 1990) . In contrast, mutation at the Thr-58/Ser-62 sites has been shown to aect the biological function of the c-Myc proteins. The loss of Thr-58 is found in the majority of v-Myc proteins (Papas and Lautenberger, 1985) and in c-Myc proteins from Burkitt's lymphomas (Bhatia et al., 1993) . v-Myc proteins that have not lost Thr-58 are weakly transforming relative to v-Myc proteins that have lost Thr-58 (Palmieri et al., 1983; Chen et al., 1989) . Restoring Thr-58 to the MC29 v-Myc protein restrains its ability to transform ®broblasts and myelomonocytic cells (Symonds et al., 1989) , while mutating Thr-58 in c-Myc to an alanine increases its ability to induce foci in embryo ®broblasts (Frykberg et al., 1987) . Therefore, it appears that Thr-58 phosphorylation transduces a negative growth signal. In vivo and in vitro, phosphorylation of Thr-58 is dependent on a prior phosphorylation of Ser-62 (Lutterbach and Hann, 1994) .
The role of Ser-62 phosphorylation in c-Myc is controversial. Pulverer et al. (1994) demonstrated that a Ser-62 mutation severely reduces the ability of c-Myc to co-transform rat embryo ®broblasts with Ha-ras, while a Thr-58 mutation enhances transformation. In contrast Henricksson et al. (1993) has shown that a mutation at either Thr-58 or Ser-62 enhances the ability of Rat 1A cells to grow in soft agar. We have previously shown that the in vivo phosphorylation of Ser-62 is stimulated by mitogens and appears to be signi®cantly blocked in mitosis (Lutterbach and Hann, 1994) . In addition, it is unclear if phosphorylation has any aect on the ability of c-Myc to transactivate. Gupta et al. (1993) have shown that mutation at either Thr-58 or Ser-62 impairs c-Myc transactivation of EMS sequences, whereas we did not observe signi®cant eects with these phosphorylation site mutants (Lutterbach and Hann, 1994) . Recent reports suggest that phosphorylation at the N-terminus does aect the interaction of c-Myc with a p107 protein complex (Gu et al., 1994; Hoang et al., 1995) . Transactivation by a Gal4-Myc fusion protein is suppressed by coexpression of p107, but a Gal4-Myc fusion protein with a mutation at Thr-58 is not suppressed by coexpression of p107 (Gu et al., 1994; Hoang et al., 1995) .
In this report, we have used an extensive series of deletion constructs and site-speci®c mutations to identify ®ve new phosphorylation sites in c-Myc at Ser-82 and Ser-164 in the N-terminal transactivation domain and Ser-293 and Ser-343/Ser-344 in the Cterminal domain, in addition to the previously identi®ed phosphorylation sites at Thr-58, Ser-62, Ser-71 and Ser-347/348 (Luscher et al., 1989; Lutterbach and Hann, 1994) . Previous studies have analysed overexpressed protein only, whereas in this study we describe regulation of phosphorylation in the endogenous protein. Analysis of the c-Myc protein in various cell lines has revealed that the endogenous cMyc has a very dierent phosphorylation pattern compared with the overexpressed, exogenous c-Myc which is commonly used for phosphorylation and functional studies. In addition, c-Myc phosphorylation was distinctly dierent in immortalized cell lines compared with primary cells, while no signi®cant dierences were seen between transformed and nontransformed cell lines. Finally, the role of the newly identi®ed phosphorylation sites and the requirement for phosphorylation of the transactivation domain was tested in transactivation assays.
Results

c-Myc is phosphorylated at multiple proline-directed kinase consensus sites
Our previous mapping experiments revealed the presence of several major phosphopeptides in addition to the Thr-58, Ser-62, and Ser-71 containing peptides that we had identi®ed (Lutterbach and Hann, 1994) . Our ®rst approach to localizing these phosphorylation sites utilized a series of deletion constructs of c-Myc shown in Figure 1 . These constructs were transiently transfected into COS cells and the expressed proteins were recovered from 32 P-orthophosphate-labeled cells for protease mapping and phosphoamino acid analysis as described in the Materials and methods. As summarized in Figure 1 , deletion constructs that resulted in the loss of a phosphopeptide are represented above the schematic by bold lines while the deletion constructs resulting in wildtype phosphorylation patterns are shown below the schematic.
We next proceeded to introduce alanine substitutions at candidate serines in the deletion intervals and to compare the resultant 2-D maps with wildtype protein using thermolysin. Thermolytic 2-D maps of wildtype murine c-Myc-2 protein revealed a pattern of phosphopeptides designated a, b, c, d, e, f and g (Figure 2a ). Peptides a, b, and c have previously been characterized and result from phosphorylation at Ser-71, Thr-58/Ser-62 (doubly phosphorylated peptide), and Ser-62 (singly phosphorylated peptide), respectively (Lutterbach and Hann, 1994) . Phosphoamino acid analysis revealed that the remaining peptides d, e, f, and g contained phosphoserine only (data not shown). Two serines at amino acids 80 and 82 were candidate phosphorylation sites in thermolytic peptide d which was absent in the c-Myc 78-95 deletion construct (Figure 1 ). Site-directed mutagenesis at these residues revealed that an alanine substitution at Ser-80 resulted in a wildtype phosphorylation pattern (data not shown), while a substitution at Ser-82 resulted in the loss of thermolytic peptide d (Figure 2a) . Two serine residues, Ser-162 and Ser-164, were also candidate phosphorylation sites in peptide e which was absent in the 160-170 deletion construct. Surprisingly, individual point mutations at either serine residue resulted in a wildtype thermolysin map (data not shown). We then proceeded to combine alanine substitutions at Ser-162 and Ser-164, and this combination resulted in the loss of peptide e ( Figure  2a ). Because individual mutations at either residue did not alter the mobility of thermolytic fragment e, we conclude that this fragment is not doubly phosphorylated at Ser-162 and Ser-164, but rather that the loss of phosphorylation at one serine is compensated by phosphorylation at the neighboring serine.
We next turned to analysis of the phosphopeptide(s) designated peptide g. As we will discuss shortly, we have evidence that these phosphopeptides are derived from a single thermolytic fragment and thus we are grouping them as one phosphopeptide. By deletion mapping (Figure 1 ) we localized these phosphopeptides to a region of c-Myc that contains the previously described casein kinase II phosphorylation sites at Ser-347 and Ser-348 (Luscher et al., 1989) . The high electrophoretic mobility and low chromatographic mobility of peptide g are consistent with the positively charged, hydrophilic amino acids in this region. When we substituted alanine residues at both Ser-347 and Ser-348 we observed only a partial loss of peptide g and an alteration in its mobility (likely due to the increased hydrophobicity and decreased phosphorylation) such that it consistently migrated above peptide f (Figure 2a ). Since we did not see a complete loss of phosphopeptide g, we searched for other potential phosphorylation sites within this thermolytic fragment. Combining alanine substitutions at both Ser-343 and Ser-344 with substitutions at Ser-347 and Ser-348 led to a complete loss of peptide g (Figure 2a ). Similar to the Ala-347/348 protein, when Ser-343 and Ser-344 were replaced with alanines we observed a mobility shift in peptide g (data not shown). Our evidence thus suggests that in addition to the cluster of N-terminus phosphorylation sites, c-Myc contains multiple phosphorylation sites adjacent to the DNA binding domain (amino acids 356-367).
We considered the possbility that additional phosphorylation sites existed in c-Myc that were not detected by thermolytic mapping analysis due to The material near the origin of our thermolysin maps, which contains both phosphoserine and phosphothreonine (data not shown), may represent such insoluble phosphopeptide fragments and/or partially digested fragments which are too large to be resolved. Therefore we analysed the phosphopeptide patterns produced by other proteases. The chymotryptic phosphopeptide map of wildtype c-Myc protein revealed multiple phosphopeptides that we have designated A, B, C D, E and E' in the wildtype cMyc protein (Figure 3a ). Based on phosphoamino acid analysis and alanine substitution analysis, peptides A, B, and C are phosphoisomers of the same chymotryptic fragment, containing the previously described phosphorylation sites. Phosphopeptide A is phosphorylated at Thr-58, Ser-62, and Ser-71, peptide B is phosphorylated at Thr-58 and Ser-62, and peptide C is phosphorylated at Ser-62 only (data not shown). Thus we found that an alanine substitution at Ser-71 resulted in a loss of the triply phosphorylated peptide A ( Figure  3a) . Similar results are obtained with an Ala-58 substitution (data not shown). Since Thr-58 phosphorylation is dependent on a prior phosphorylation at Ser- Next, the previously unidenti®ed chymotryptic peptides were examined. As shown in Figure 3a , peptide D is removed by an Ala-82 substitution, revealing that both thermolytic peptide d (Figure 2a ) and chymotryptic peptide D resulted from Ser-82 phosphorylation. Peptides E/E' were shown to contain only phosphoserine and were found to have identical mobilities upon secondary digestion with proline endopeptidase, suggesting that a partial digest with chymotrypsin produces these two phosphopeptides. Deletion mapping indicated that Ser-288 and/or Ser 293 were potential phosphorylation sites in peptides E/ E' ( Figure 1) ; however, only an alanine substitution at Ser-293 resulted in the loss of peptides E/E' ( Figure  3a) . Phosphopeptides containing Ser-164 and the Cterminal phosphorylation sites that we observed by thermolytic mapping were not resolved on the chymotryptic maps, possibly due to factors such as size or solubility of the chymotryptic fragment. However, alanine substitutions at these serines did cause the loss of speci®c tryptic phosphopeptides relative to wildtype c-Myc (data not shown).
Our mapping analysis at this point has revealed the presence of ten major phosphorylation sites in c-Myc as summarized in Figure 3c . We have found ®ve sites in the transactivation domain (Kato et al., 1990 ) and a cluster of ®ve sites in the C-terminus adjacent to the basic region and nuclear localization motifs (Dang and Lee, 1988) . Interestingly, except for the Casein kinase II sites, all of the phosphorylation sites described here ( Figure  2b and Figure 3b ) are in the S/T-P consensus sequence for proline directed kinases (Pearson and Kemp, 1991) .
Altered Thr-58 phosphorylation occurs with c-Myc overexpression and immortalization
All previous analyses of c-Myc phosphorylation have relied exclusively on exogenous protein overexpressed in various cell lines or on cell lines that highly overexpress the protein (Luscher and Eisenman, 1992; Lutterbach and Hann, 1994; Henricksson et al., 1993) , since low levels of c-Myc expression in nontransformed and primary cell lines (Hann and Eisenman, 1984) has made phosphorylation studies of the endogenous cMyc protein more dicult in these cell types. We were concerned that phosphorylation of a highly overexpressed c-Myc protein may be regulated in a dierent manner than the endogenous protein. Alternatively, the overexpressed protein could be a substrate for kinases that do not normally interact with c-Myc expressed at physiological levels. We began our analysis by comparing phosphorylation of endogenous c-Myc in NIH3T3 cells with phosphorylation of exogenous murine c-Myc overexpressed in NIH3T3 cells. As shown in Figure 4 , when c-Myc was overexpressed, we consistently found that thermolytic peptide c (single phosphorylation at Ser-62) was a very minor phosphoisomer of c-Myc, whereas peptide b (double phosphorylation at Thr-58 and Ser-62) was the major phosphopeptide. This is very similar to our previous observations in COS cells overexpressing cMyc (Figure 2 , Lutterbach and Hann, 1994) . In contrast, the endogenous c-Myc in NIH3T3 cells contained an abundance of peptide c (Figure 4 , compare peptides b and c in endogenous murine and exogenous murine). Therefore, there is a striking dierence in the stoichiometry of phosphorylation at Ser-62 and Thr-58 between the overexpressed, exogenous c-Myc protein and the endogenous protein. We also observed this dramatic increase in Thr-58 phosphorylation upon c-Myc overexpression in human or avian cells (data not shown), revealing that this regulation occurs as a general consequence of c-Myc overexpression in many cell types.
Since c-Myc has been implicated in the processes of transformation and immortalization (Land et al., 1983) , we were also interested in examining the phosphorylation of endogenous c-Myc protein in various nontransformed and transformed immortal cell lines as well as several primary cells from different tissue sources. We ®rst compared a number of transformed and nontransformed human and murine cell lines for dierences in phosphorylation patterns. Surprisingly, we did not ®nd consistent dierences in transformed cells. We found that the phosphorylation of c-Myc in the nontransformed NIH3T3 cells (Figure  4 ), Balb/MK cells (immortal keratinocytes, Figure 5 ), CV-1 and HaCaT cells (data not shown) was similar to c-Myc phosphorylation from transformed COS and HeLa cells (data not shown). We had also observed similar patterns of phosphorylation in c-Myc from Jurkat cells and Burkitt's lymphoma lines as well (Hoang et al., 1995) . These results are also consistent with our previous observation that cotransfection of cMyc with an activated ras oncogene did not aect cMyc phosphorylation (Lutterbach and Hann, 1994) . From these results we conclude that c-Myc phosphorylation is not signi®cantly aected by the transformation process.
Since c-Myc has been implicated in the immortalization process, we also analysed phosphorylation patterns in primary cells as well. As shown in Figure  5 , c-Myc from primary keratinocytes exhibited a greater amount of the doubly phosphorylated Thr-58/ Ser-62 peptide b compared to the Ser-62 singly phosphorylated peptide c. In contrast, in an immortal mouse keratinocyte cell line (Balb/MK), we consistently observed a pattern where peptide c was a major Analysis of primary rat hepatocytes, rat embryo ®broblasts, and primary human foreskin ®broblasts revealed similar phosphorylation patterns as seen in primary keratinocytes (data not shown). Thus, although c-Myc phosphorylation is not signi®cantly aected by transformation, we observed an increase in Ser-62 phosphorylation and a decrease in phosphorylation at Thr-58 in immortalized cells.
Eects of phosphorylation on transactivation
Our previous mutational analysis revealed that individual phosphorylation at Thr-58, Ser-62, or Ser-71 did not aect the ability of c-Myc to transactivate a multimerized EMS-CAT construct (Lutterbach and Hann, 1994 ). Because we have now identi®ed a cluster of phosphorylation sites in the transactivation domain, we were interested in testing the eect of a combined loss of phosphorylation in this region. We therefore produced a c-Myc protein with decreasing amounts of phosphorylation in the transactivation domain by combining alanine substitutions as described in Figure 6a (constructs A and B). These constructs were transiently transfected into NIH3T3 cells with the [EMS] 4 -CAT reporter plasmid and a SV40 b-galactosidase expression plasmid to control for transfection eciencies. Immunoprecipitation revealed that the proteins listed in 6a were expressed at similar levels compared to wildtype cMyc protein in these CAT assays, and phosphopeptide mapping con®rmed that these proteins contained the predicted alterations in their phosphorylation sites (data not shown). However, the proteins expressed from constructs A and B were very similar to wildtype c-Myc in their ability to transactivate the EMS-CAT construct (Figure 6b , 6c and data not shown). We also combined alanine substitutions such that N-terminal phosphorylation occurred only at Thr-58 and Ser-62, which are frequent targets of mutation in Burkitt's lymphomas (constructs C and D, Figure 6a ). Again, we found that the transcriptional activity of these proteins was also unaected relative to wildtype c-Myc (Figure 6b , 6c and data not shown).
In this study we have found that Ser-62 phosphorylation was enhanced in the endogenous c-Myc protein of many cell lines. We also previously found that cMyc A58 (and v-Myc isolates with mutations at Thr-58) have an increase in this Ser-62 single phosphorylated isomer (Lutterbach and Hann, 1994) . We therefore tested the eects of this modi®cation in cMyc by combining alanine substitutions (constructs E and F, Figure 6a ) so that c-Myc was phosphorylated only at Ser-62 in the N-terminus. As with the other mutated c-Myc proteins, these also transactivated EMS sequences similar to wildtype c-Myc (Figure 6b, 6c and data not shown). We also tested a one copy EMS- Finally, we also tested alanine substitutions at Ser-343/344 and at Ser-293 individually or in combination with the casein kinase II sites at Ser-347/348 ( Figure  6a , constructs G and H). In some cases phosphorylation in or near the basic region of other DNA binding proteins has been shown to inhibit their activity (Hunter and Karin, 1992; Meek and Street, 1992) . However, we again did not observe signi®cant dierences in transactivation potential of the altered proteins compared to wildtype (Figure 6b, 6c and data not shown). As negative controls we used an Nterminally-truncated c-Myc (~-c-Myc) and a c-Myc having a deletion of the basic region (c-Myc~BR). Both of these lost the ability to transactivate EMS-CAT (data not shown), as previously observed by Kretzner et al. (1992) .
Discussion
Localization of c-Myc phosphorylation sites
In this investigation we have localized the remaining major sites of phosphorylation in c-Myc using a combination of proteases and a panel of deletion and alanine substitution constructs. Our results indicate that at least ten phosphorylation sites are present in cMyc. Interestingly, we observed that ®ve phosphorylation sites (Thr-58, Ser-62, Ser-71, Ser-82 and Ser-164) are located in an N-terminal 164 amino acid region of c-Myc that functions as a transactivation domain (Kato et al., 1990) . We also found that in addition to previously described C-terminus phosphorylation at Ser-347 and Ser-348 (Luscher et al., 1989) , c-Myc is also phosphorylated at Ser-343/344 and at Ser-293 near the DNA binding basic region. These sites (except for the casein kinase II sites at Ser-347/348) are in favorable consensus sequences for proline directed kinases (Pearson and Kemp, 1991) . Although these ten sites are the major phosphorylated residues in most untreated, normally growing cells, additional phosphorylation in c-Myc appears to be more highly regulated under speci®c conditions. We have observed a TPA-stimulated phosphorylation of c-Myc at an unidenti®ed serine residue (Lutterbach and Hann, unpublished observations). This is potentially interesting, since functionally signi®cant residues in c-Jun have been shown to be regulated by TPA (Smeal et al., 1991) .
Functional implications for phosphorylation of c-Myc
Several previous studies have suggested a role for Thr-58 phosphorylation in c-Myc function. Since mutation at or near Thr-58 is observed in most v-Myc proteins and many c-Myc proteins from Burkitt's lymphomas, it has been suggested that Thr-58 is an inhibitory modi®cation for c-Myc function. Based on this idea we have examined phosphorylation of the c-Myc protein in several transformed and non-transformed cell lines. However, the phosphorylation patterns of the endogenous c-Myc protein in COS cells and CV-1 cells were very similar, revealing that the transforming SV40 T antigen did not alter c-Myc phosphorylation. In addition, analysis of the endogenous c-Myc protein in HeLa cells suggested that the transforming HPV E6 and E7 proteins also did not have signi®cant eects on c-Myc phosphorylation. We had also previously observed that coexpression of activated ras with cMyc did not lead to signi®cant changes in c-Myc phosphorylation (Lutterbach and Hann, 1994) . Taken together, these results suggest that c-Myc phosphorylation is not altered by the transformation process. This is in contrast to c-jun and c-fos which show alterations in phosphorylation on overexpression of transforming oncogenes such as v-src, v-ras, and v-sis (Smeal et al., 1992; Deng and Karin, 1994) .
Interestingly, we did observe signi®cant dierences in the ratio of Thr-58/Ser-62 phosphorylation between immortal and primary cells, especially when comparing primary and immortal keratinocytes. Primary keratinocytes had comparable or greater levels of doubly phosphorylated Thr-58/Ser-62 compared with singly phosphorylated Ser-62. However, in immortalized keratinocytes Ser-62 phosphorylation was greatly enhanced compared to the Thr-58/Ser-62 phosphorylation, suggesting that upregulation of Ser-62 phosphorylation and downregulation of phosphorylation at Thr-58 may contribute to the immortalization process. These results are consistent with the hypothesis that enhanced Ser-62 phosphorylation results in a more active form of the c-Myc protein, while Thr-58 phosphorylation yields a less active form of c-Myc. This hypothesis is also consistent with the enhancement of Thr-58 phosphorylation that occurs upon overexpression of c-Myc. Since overexpressed, deregulated c-Myc can induce apoptosis (Askew et al., 1991; Evan et al., 1992) , stimulation of the potentially inhibitory Thr-58 kinase may be a cellular mechanism to inhibit c-Myc function. Alternatively, the overexpressed c-Myc protein may be processed and/or localized dierently by the cell compared to the endogenous c-Myc protein.
Although c-Myc phosphorylation does appear to have functional implications, as discussed in the Introduction, and despite the results of Gupta et al. (1997) that c-Myc phosphorylation does regulate transactivation of EMS sequences, we and others (C Dang personal communication, and Henricksson et al., 1993) have been unable to demonstrate an eect of cMyc phosphorylation on transcriptional activation through EMS sequences. Individual alanine substitutions at the ®ve phosphorylation sites in the N-terminal transactivation domain did not alter the transactivation capabilities of c-Myc. In addition, various combinations of alanine substitutions were found to have no signi®cant eect on transactivation relative to the wildtype protein. A dissociation between c-Myc biological function and transactivation also occurs with a c-Myc protein containing a deletion of amino acids 106-143. This deletion results in a transformation defective c-Myc protein that is still an ecient transactivator (Kato et al., 1990; Amin et al., 1993; Bello-Fernandez et al., 1993) . There are several possible explanations for these results. The EMS reporter construct may not re¯ect a physiological cMyc-regulated sequence, and it will therefore be important to test candidate c-Myc-regulated promoter targets. It may also be possible that phosphorylation is c-Myc Phosphorylation B Lutterbach and SR Hann important for c-Myc function in a tissue speci®c manner. c-Myc has been isolated as an oncogene primarily in hematopoietic cells, and deletion mutants of v-Myc have been described that are de®cient for transformation of macrophages but not ®broblasts (Ramsay et al., 1980) . Although the full biochemical and physiological role for phosphorylation in c-Myc remains unresolved, there are clear functional implications for phosphorylation of c-Myc. Thr-58 phosphorylation has been lost by mutation in the v-Myc proteins and in at least 60% of primary Burkitt's lymphomas (Bhatia et al., 1993) , and loss of this site contributes to the enhanced transforming character of v-Myc (Frykberg et al., 1987; Palmieri et al., 1983; Filardo and Humphries, 1996; Symonds et al., 1989) . Previous studies have also linked deregulated c-Myc expression with cell immortalization, and in this study we observed decreased Thr-58 phosphorylation and increased Ser-62 phosphorylation in immortalized cells relative to primary cells. Future eorts will be aimed at identifying the kinases that phosphorylate c-Myc and establishing their role in c-Myc biochemical function.
Materials and methods
Cell lines
NIH3T3 and COS-7 cells were obtained from American Type Culture Collection (ATCC). Primary keratinocytes and HaCaT cells (Boukamp et al., 1988) were obtained from P Hauser (Vanderbilt), primary hepatocytes were obtained from R Carver (Vanderbilt) and rat embryo ®broblasts were obtained from C Dang (Johns Hopkins). COS cells and ®broblasts were cultured in Dulbecco's modi®ed Eagle medium (DMEM, GIBCO Laboratories, Grand Island, N.Y.) supplemented with 10% calf serum (de®ned-supplemented; Hyclone Laboratories, Logan, Utah) and 1000 U of 1:1 penicillin-streptomycin (Gibco Laboratories) per ml, and were maintained at 378C in a humidi®ed 5% CO 2 atmosphere. Keratinocytes and human epithelial HaCaT cells (Boukamp et al., 1988) were cultured in DMEM containing 10 ng/ml EGF and 8% dialyzed fetal calf serum.
Plasmids
Construction of the c-Myc eukaryotic expression vectors has been described previously . The murine c-Myc cDNA has a mutation at the CUG upstream initiation site to prevent synthesis of the c-Myc-1 protein . In addition, the murine penultimate Cterminal glycine was mutated to arginine so that the avianspeci®c antiserum (anti-av-myc 12C) can selectively immunoprecipitate the exogenous murine protein and not the endogenous murine or human c-Myc proteins (Spotts and Hann, 1990) .
Single stranded DNA form murine c-Myc in the pRcCMV vector (Invitrogen) was used to create the deletion constructs and point mutations described in the text using dut-ung-E-coli as previously described (Kunkel, 1985) . Mutations were veri®ed by sequence analysis. The pRcCMV expression vector was used to transiently express the full length c-Myc 2 proteins for peptide mapping and for CAT assays. The deletion constructs 91-103, 145-262, 265-295, 312-368, 371-412 , and 414-433 have been described in (Stone et al., 1987) . The [EMS] 4 -CAT reporter plasmid (M4 min CAT) has been previously described (Kretzner et al., 1992) and was a gift from L Kretzner and R Eisenman.
Cell transfection and labeling
Cells were transfected by the calcium phosphate method (Wigler et al., 1979) . For transactivation assays, cells were plated at 1 ± 2610 6 per 10 cm dish. Approximately 24 h later 1 ml of calcium phosphate-precipitated DNA containing 3 mg of the reporter plasmid, 1 mg of SV40 driven bgalactosidase plasmid, and 3 mg of c-Myc expression vector or 3 mg of the empty vector was added to the cells for 4 h, after which time the media was aspirated and the cells were glycerol shocked. After 48 h, extracts were prepared and equalized for b-galactosidase activity before determining CAT activity as previously described (Norton and Con, 1985) . For expression of the exogenous c-Myc protein, approximately 5 ± 10610 6 COS or NIH3T3 cells were transfected with 10 mg expression plasmid per 10 cm plate and labeled 40 h after transfection (for 3 h) with 1 mCi of [ 32 P]-orthophosphate at 378C in phosphate free medium. For mapping of the endogenous c-Myc protein, approximately 5610 7 cells were labeled with 12.5 mCi of [ 32 P]-orthophosphate (ICN) for 3 h at 378C in phosphate-free medium.
Immunoprecipitation
Labeled cells were washed with 10 mM Tris-HCl, pH 8, 150 mM NaCl and solubilized in cold antibody lysis (Ab) buer (Hann et al., 1983) containing 10 mM iodoacetamide, 0.1 mM sodium vanadate, 15 mM sodium¯uoride, 0.1 T.I.U. aprotinin, and 0.1 mM PMSF. The cellular lysate was then sonicated, precleared with Staphylococcus aureus membranes (Immuno-Precipitin; Bethesda Research Laboratories, Bethesda, Md.), and immunoprecipitated with 5 mg of the indicated antibody and Immuno-precipitin as previously described (Hann et al., 1983) . Transiently-expressed murine c-Myc proteins were speci®cally immunoprecipitated with the anti-av-myc 12C antibody, endogenous murine c-Myc proteins were immunoprecipitated with the anti-mu-myc 12C antibody, and human c-Myc proteins were immunoprecipitated with the anti-hu-myc 12C antibody. Preparation and characterization of these species-speci®c antibodies has been previously described (Spotts and Hann, 1990) .
Peptide mapping and phosphoamino acid analysis [ 32 P]-orthophosphate-labeled c-Myc proteins were immunoprecipitated, separated by SDS ± PAGE, transferred to nitrocellulose, and digested o the membrane with 10 ± 20 mg of the indicated proteases, followed by performic acid oxidation (1 h at 08C) and repeated lyophilization as previously described (Boyle et al., 1991) . Secondary digestion with proline endopeptidase (ICN) digestion was performed as previously described (Lutterbach and Hann, 1994) . The digested fragments were separated in the ®rst dimension by electrophoresis using a Hunter thin layer electrophoresis chamber in pH 1.9 buer (1.5 kV, 20 min), and then separated in the second dimension by ascending chromatography in phosphochromatography buer (Boyle et al., 1991) . The origin of loading was located in the lower left corner of the thin-layer cellulose plate (Merck) unless otherwise indicated.
Phosphoamino acid analysis was conducted on in vitro phosphorylated peptides or proteins and in vivo labeled proteins by acid hydrolysis at 1108C in 6 M HCl for 1 h. Samples were then lyophilized and analysed ®rst by electrophoresis at pH 1.9 for 20 min at 1.5 kV (with phosphoserine, phosphothreonine, and phosphotyrosine markers) and then by electrophoresis in the second dimension at pH 3.5 for 16 min at 1.6 kV. Markers were visualized with ninhydrin. 
